Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.CLYM · Entity 5064 | Director | June 05, 2026 | June 08, 2026 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | See Remarks | January 19, 2022 | January 21, 2022 |
| SEELOS THERAPEUTICS, INC.SEEL · Entity 93662 | Director | January 06, 2021 | January 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-04 | Direct | 40,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
Fulcrum Therapeutics, Inc.
Report date January 19, 2022 · Filed January 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.69 · Expires 2032-01-18 | Direct | 140,890 |
Reported balance
After 2022-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-19 · Grant · Acquired 140,890 · Balance 140,890 F1: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.
SEELOS THERAPEUTICS, INC.
Report date January 06, 2021 · Filed January 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2031-01-06 | Direct | 16,000 |
Reported balance
After 2021-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-06 · Grant · Acquired 16,000 · Balance 16,000 F1: 1/12th of the shares subject to the option shall vest on February 6, 2021, and 1/12th of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on February 6, 2021, and 1/12th of the shares subject to the option shall vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 22:26 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262270 · ownership.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:11 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-082323 · ownership.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 21:23 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001415889-24-018467 · form4-06282024_090644.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:08 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031527 · doc4.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed Jun 1, 2022 21:02 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001209191-22-033206 · doc4.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 140,890 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0000899243-22-002880 · doc4.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,890 Underlying: Common Stock · 140,890 shares Expires 2032-01-18 F1 · derivative.exercise_date: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014591 · doc4.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: This option was granted on April 1, 2021 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of April 1, 2021. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 21:30 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001136261-21-000004 · primary_doc.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-01-06 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 6, 2021, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 15, 2020 Filed May 15, 2020 21:19 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001136261-20-000120 · primary_doc.xml · derivative · entry 2 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-05-15 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on June 15, 2020, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 15, 2020 Filed May 15, 2020 21:19 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001136261-20-000120 · primary_doc.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option shall vest on May 15, 2021, and 1/36th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.